Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.
Lee CP, Taylor NJ, Attard G, Pacey S, Nathan PD, de Bono JS, Temple G, Bell S, Stefanic M, Stopfer P, Tang A, Koh DM, Collins DJ, d'Arcy J, Padhani AR, Leach MO, Judson IR, Rustin GJ. Lee CP, et al. Among authors: nathan pd. Oncologist. 2015 Apr;20(4):368-9. doi: 10.1634/theoncologist.2014-0250. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795637 Free PMC article. Clinical Trial.
Epithelial ovarian cancer: a review of current management.
Guppy AE, Nathan PD, Rustin GJ. Guppy AE, et al. Among authors: nathan pd. Clin Oncol (R Coll Radiol). 2005 Sep;17(6):399-411. doi: 10.1016/j.clon.2005.05.009. Clin Oncol (R Coll Radiol). 2005. PMID: 16149282 Review.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri TK. Larkin J, et al. Oncologist. 2023 Apr 6;28(4):333-340. doi: 10.1093/oncolo/oyac243. Oncologist. 2023. PMID: 36576173 Free PMC article. Clinical Trial.
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Eisen T, Marais R, Affolter A, Lorigan P, Robert C, Corrie P, Ottensmeier C, Chevreau C, Chao D, Nathan PD, Jouary T, Harries M, Negrier S, Montegriffo E, Ahmad T, Gibbens I, James MG, Strauss UP, Prendergast S, Gore ME. Eisen T, et al. Among authors: nathan pd. Br J Cancer. 2011 Jul 26;105(3):353-9. doi: 10.1038/bjc.2011.257. Epub 2011 Jul 12. Br J Cancer. 2011. PMID: 21750549 Free PMC article. Clinical Trial.
Vemurafenib in melanoma.
Shaw HM, Nathan PD. Shaw HM, et al. Among authors: nathan pd. Expert Rev Anticancer Ther. 2013 May;13(5):513-22. doi: 10.1586/era.13.24. Expert Rev Anticancer Ther. 2013. PMID: 23617343 Review.
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. McArthur GA, et al. Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641. Ann Oncol. 2017. PMID: 27993793 Free article. Clinical Trial.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176. Ann Oncol. 2017. PMID: 28475671 Free PMC article. Clinical Trial.
119 results